Male Hypogonadism Market Size (2024 - 2029)

The male hypogonadism market is anticipated to experience growth driven by factors such as the increasing incidence and prevalence of the condition, advancements in therapy technologies, and heightened awareness regarding hypogonadism and its treatment options. This market expansion is influenced by the condition's impact on various health risks, including type 2 diabetes and cardiovascular diseases, particularly in older males. The market's dynamics are shaped by the need for effective management and treatment solutions for testosterone deficiency, which affects a significant number of men across different age groups.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Endocrinology Drugs Research Testicular Male Hypogonadism Market Market Size

Market Size of Male Hypogonadism Industry

Male Hypogonadism Market Overview
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 5.10 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Male Hypogonadism Market Major Players

*Disclaimer: Major Players sorted in no particular order

Male Hypogonadism Market Analysis

The Male Hypogonadism Market is expected to register a CAGR of 5.1% during the forecast period. Male hypogonadism or testosterone deficiency is a condition in which the body doesn't produce enough of the hormone that plays a key role in development and masculine growth during puberty or enough sperm or both. Hypogonadism may occur at any age, and the consequences differ, according to when it starts. In adult men, within a few weeks of the onset of testosterone deficiency symptoms begin. Hypogonadism may increase the risk for type 2 diabetes, cardiovascular disease, premature death in older men, metabolic syndrome, and Alzheimer's disease.

According to Boston University School of Medicine, approximately 4 to 5 million men in the United States, are affected with hypogonadism and low testosterone levels are commonly seen in older males. More than 60% of men over 65 years of age have free testosterone levels below the normal values of men between 30 to 35 years of age. A Study published in the Indian Journal of Endocrinology and Metabolism in the year 2017, estimates that prevalence of hypogonadism in type 2 diabetes patients was found to be 20.7%. Furthermore, the prevalence rate of hypogonadism in patients with type 2 diabetes was moderate with highest number of patients belonging to age group 50-59 year.

Increase in incidence and prevalence of hypogonadism, technological advancements in male hypogonadism therapy and rise in awareness about hypogonadism and its treatment option are the key driving factors in male hypogonadism market.

Male Hypogonadism Industry Segmentation

As per the scope of the report, Male hypogonadism or testosterone deficiency, is a failure of the testes to produce the male sex hormone testosterone, sperm, or both. It can be due to the result of a disease process involving the hypothalamus and pituitary gland or testicular disorder. Male hypogonadism market is segmented by therapy type, application and geography.

By Therapy Type
Testosterone Replacement Therapy
Gonadotropin-Releasing Hormones Therapy
Human Chorionic Gonadotropin (hCG)
Follicle-stimulating Hormone (FSH)
Gonadotropin-releasing Hormone (GnRH)
Other Gonadotropin Replacement Therapies
By Application
Kallmann Syndrome
Klinefelters Syndrome
Pituitary Disorders
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Male Hypogonadism Market Size Summary

The Male Hypogonadism Market is poised for steady growth, driven by an increasing incidence of hypogonadism and advancements in therapy options. This condition, characterized by insufficient testosterone production, affects men of all ages and is particularly prevalent among older males, with a significant portion experiencing low testosterone levels. The market is influenced by the rising awareness of hypogonadism and its treatment, alongside technological innovations in therapy. Gonadotropin-releasing hormone therapy is a key segment, holding a substantial market share due to its effectiveness in regulating male reproductive functions. The prevalence of hypogonadism is notably higher in men with obesity and those in poor health, further propelling market demand.

North America is expected to dominate the global male hypogonadism market, attributed to the high incidence of the condition and increased awareness of treatment options in the region. The market's growth is supported by a robust healthcare infrastructure and ongoing research and development efforts. The competitive landscape is fragmented, with major players like Endo International Plc, AbbVie Inc, and Pfizer Inc focusing on technological advancements and product innovation to cater to the growing demand. These companies, along with others such as Allergan Plc and Teva Pharmaceutical Industries Ltd, are key contributors to the market's expansion, leveraging their expertise to address the needs of men affected by hypogonadism.

Explore More

Male Hypogonadism Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Cases of Male Hypogonadism Worldwide

      2. 1.2.2 Technological Advancements in Male Hypogonadism Therapy

      3. 1.2.3 Growing Awareness Among Individuals Regarding Hypogonadism Treatment

    3. 1.3 Market Restraints

      1. 1.3.1 High Side Effects Associated with Treatment

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Therapy Type

      1. 2.1.1 Testosterone Replacement Therapy

      2. 2.1.2 Gonadotropin-Releasing Hormones Therapy

        1. 2.1.2.1 Human Chorionic Gonadotropin (hCG)

        2. 2.1.2.2 Follicle-stimulating Hormone (FSH)

        3. 2.1.2.3 Gonadotropin-releasing Hormone (GnRH)

        4. 2.1.2.4 Other Gonadotropin Replacement Therapies

    2. 2.2 By Application

      1. 2.2.1 Kallmann Syndrome

      2. 2.2.2 Klinefelters Syndrome

      3. 2.2.3 Pituitary Disorders

      4. 2.2.4 Other Applications

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Male Hypogonadism Market Size FAQs

The Male Hypogonadism Market is projected to register a CAGR of 5.10% during the forecast period (2024-2029)

Endo International Plc, AbbVie Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd and Allergan Plc are the major companies operating in the Male Hypogonadism Market.

Male Hypogonadism Market Report Snapshots

Male Hypogonadism Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)